Investigational therapy for B-cell malignancies offers three targets in one CAR T cell
Healio: Reshmi Parameswaran, assistant professor at the School of Medicine, discussed research into BAFF ligand-based CAR T-cell therapy. “Given my previous experience with BAFF receptor antibodies as a therapeutic, my thoughts moved toward the ability to use the ligand BAFF as part of a CAR-T for hematologic malignancies,” said Parameswaran. “I thought this could be especially useful for B-cell cancers because nearly all of them express BAFF receptors.”